Results 181 to 190 of about 9,605 (202)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Journal of Clinical Medicine, 2022
Trinidad Montero-Vilchez, CARLOS Cuenca-Barrales, Antonio Martínez-López   +2 more
exaly  

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics, 2014
Valentin Brodszky, Petra Baji, Orsolya Balogh   +2 more
exaly  

Biosimilars – Biosimilars: ja, aber

Aktuelle Rheumatologie, 2015
openaire   +1 more source

Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs

AAPS Journal, 2019
Francesca Civoli, Meenu Wadhwa, Andrew Exley   +2 more
exaly  

Clinical considerations for biosimilar antibodies

European Journal of Cancer, Supplement, 2013
Håkan Mellstedt
exaly  

Japanese regulation of biosimilar products: past experience and current challenges

British Journal of Clinical Pharmacology, 2016
Teruyo Arato
exaly  

Regulation of biosimilar medicines and current perspectives on interchangeability and policy

European Journal of Clinical Pharmacology, 2018
Juan M O'Callaghan, Brendan T Griffin
exaly  

Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health

Biologicals, 2016
J Braun
exaly  

Patient Perspectives on Biosimilar Insulin

Journal of Diabetes Science and Technology, 2014
Kelly L Close
exaly  

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials

Journal of the Royal Statistical Society Series C: Applied Statistics, 2017
Haitao Pan, Ying Yuan, Jielai Xia
exaly